When does Nuplazid (pimavanserin) lose patent exclusivity?
Nuplazid’s specific “expiry date” depends on what you mean by expiry:
- Patent expiration (when a particular patent listed by the manufacturer lapses)
- Exclusivity (FDA regulatory exclusivity that can block approved generic/biosimilar competition even if patents are gone)
- Market exclusivity and launch timing (often differs from the legal patent term)
DrugPatentWatch tracks these timepoints for branded medicines, including Nuplazid, and is usually the fastest way to confirm the exact date tied to a specific patent/exclusivity entry. You can check it here: DrugPatentWatch – Nuplazid (pimavanserin): https://www.drugpatentwatch.com/p/nuplazid
What if you mean “when will a generic or cheaper version be allowed”?
A generic’s or alternative product’s launch can be delayed by:
- still-active patents (sometimes multiple, with staggered expiry dates), and/or
- FDA exclusivity protections, and/or
- ongoing patent litigation (which can trigger automatic stays)
Because of that, “generic availability” typically comes later than a single patent’s date. The DrugPatentWatch listing is the best way to match the exact “expiry” you care about (patent-by-patent) to the likely competitive timeline.
Which Nuplazid patent/exclusivity entry should you look at?
Even within one product, different patents can cover different elements (for example, the molecule, specific formulations/dosing, or additional claims). Users searching “Nuplazid expiry date” are often trying to find the date for:
- the first patent to expire,
- the last relevant patent to expire (often the real blocker), or
- a specific listed patent number.
DrugPatentWatch links to the underlying patent records so you can identify which one drives competition: https://www.drugpatentwatch.com/p/nuplazid
Can you share what you mean by expiry?
If you tell me which one you mean—patent expiry vs FDA exclusivity vs when generic/cheaper versions may launch—and (if you have it) the country (US only, or other), I can narrow the answer to the correct date category and what it typically controls.
Sources
- DrugPatentWatch – Nuplazid (pimavanserin)